Last reviewed · How we verify
Placebo Evogliptin
Placebo Evogliptin is a DPP-4 inhibitor Small molecule drug developed by Eurofarma Laboratorios S.A.. It is currently in Phase 3 development for Type 2 diabetes. Also known as: Placebo.
Evogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor.
Evogliptin is a small molecule dipeptidyl peptidase IV inhibitor used to treat Type 2 Diabetes. It is classified as an INHIBITOR drug class, specifically targeting the Dipeptidyl peptidase 4 molecular target.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Placebo Evogliptin |
|---|---|
| Also known as | Placebo |
| Sponsor | Eurofarma Laboratorios S.A. |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
DPP-4 inhibitors work by blocking the action of the enzyme DPP-4, which breaks down incretin hormones. This leads to increased levels of incretin hormones, which in turn increases insulin release in response to meals and decreases glucagon levels in the circulation during the postprandial period.
Approved indications
- Type 2 diabetes
Common side effects
- Hypoglycemia
- Nausea
- Diarrhea
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS) (PHASE2, PHASE3)
- Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control (PHASE3)
- Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control (PHASE3)
- Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases (PHASE4)
- Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2) (PHASE2)
- Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN) (PHASE4)
- A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin (PHASE3)
- Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Evogliptin CI brief — competitive landscape report
- Placebo Evogliptin updates RSS · CI watch RSS
- Eurofarma Laboratorios S.A. portfolio CI
Frequently asked questions about Placebo Evogliptin
What is Placebo Evogliptin?
How does Placebo Evogliptin work?
What is Placebo Evogliptin used for?
Who makes Placebo Evogliptin?
Is Placebo Evogliptin also known as anything else?
What drug class is Placebo Evogliptin in?
What development phase is Placebo Evogliptin in?
What are the side effects of Placebo Evogliptin?
What does Placebo Evogliptin target?
Related
- Drug class: All DPP-4 inhibitor drugs
- Target: All drugs targeting DPP-4
- Manufacturer: Eurofarma Laboratorios S.A. — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
- Also known as: Placebo
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing